MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
According to Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte, "The MaxCyte STX Scalable Transfection System can be used to transfect primary cells, cell lines, and stem cells with a range of molecules, including DNA plasmids, different types of RNA, proteins, etc., with very high efficiency. Over ten billion cells can be transfected in 30 minutes. This scale and capability can greatly improve the productivity of drug discovery laboratories. We are pleased to have the opportunity to demonstrate this technology at the A/C/T Meeting."
"We are very excited that the pharmaceutical industry views the MaxCyte STX technology as key to reducing drug discovery bottlenecks," says MaxCyte President and CEO, Doug Doerfler. "The MaxCyte STX can produce a large number of transfected cells in minutes compared to current time-consuming and inconsistent methods. Cells modified using the MaxCyte STX can be used on the research scale and in high-throughput screening assays. The faster you can get to the assay, the more compounds you can screen for biological activity, and the greater your likelihood of finding a successful drug candidate."
After the Product Demonstration, MaxCyte scientists will be available at the A/C/T Meeting to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte STX Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.
For more information, http://www.maxcyte.com/cell-based-screening.shtml.
SOURCE MaxCyte, Inc.
You May Also Like